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Abstract
Background: Rheumatoid arthritis (RA) is an inflammatory articular disease with cartilage and bone damage due to
hyperplasic synoviocyte invasion and subsequent matrix protease digestion. Although monoclonal antibodies against
tumor necrosis factor alpha (TNFa) have been approved for clinical use in patients with RA, desired therapeutic regimens
suitable for non-responders are still unavailable because etiological initiators leading to RA remain enigmatic and
unidentified.
Methodology/Principal Findings: Bacteria-induced arthritis (BIA) that simulates collagen-induced arthritis (CIA) is
developed in mice upon daily live bacterial feeding. The morphological lesions of paw erythema and edema together
with the histological alterations of synovial hyperplasia and lymphocytic infiltration emerge as the early-phase
manifestations of BIA and CIA. Bacteria- or collagen-mediated global upregulation of pro-inflammatory cytokines is
accompanied by the burst of nitric oxide (NO). Elevation of the serum NO level is correlated with decline of the blood
oxygen saturation percentage (SpO2), reflecting a hypoxic consequence during development towards arthritis. NO-driven
hypoxia is further evident from a positive relationship between NO and lactic acid (LA), an end product from glycolysis.
Upregulation of hypoxia inducible factor 1 alpha (HIF-1a) and vascular endothelial growth factor (VEGF) validates hypoxia-
induced angiogenesis in the inflamed synovium of modeling mice. Administration of the NO donor compound sodium
nitroprusside (SNP) causes articular inflammation by inducing synovial hypoxia. Anti-bacteria by the antibiotic cefotaxime
and/or the immunosuppressant rapamycin or artesunate that also inhibits nitric oxide synthase (NOS) can abrogate NO
production, mitigate hypoxia, and considerably ameliorate or even completely abort synovitis, hence highlighting that NO
may serve as an initiator of inflammatory arthritis.
Conclusions/Significance: Like collagen, bacteria also enable synovial lesions via upregulating pro-inflammatory cytokines,
triggering NO production, driving hypoxic responses, and inducing synovial angiogenesis and hyperplasia, suggesting that
sustained infection might be, in part, responsible for the onset of synovitis and arthritis in mice.
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Introduction
Rheumatoid arthritis (RA) is a chronic articular inflammatory
disease mainly affecting joints and destroying cartilage and bone,
often with severe and disabling consequences [1]. RA also affects
lungs, pleura, pericardium, sclera and subcutaneous tissue [2], so
patients with RA have an elevated risk in developing cardiovas-
cular diseases, such as arteriosclerosis and myocardial infarction
[3]. Histopathologically, RA is characterized by pronounced
synovial hyperplasia, or called pannus, a thickened membrane-like
covering of the inflammatory granulation tissue over the articular
cartilage. Like a malignant tumor, the pannus can invade and
destroy cartilage and bone by secreting matrix proteases such as
metalloproteinases and aggrecanases [4].
Although monoclonal antibody-based biologic agents that
inhibit tumor necrosis factor alpha (TNFa), including etanercept,
infliximab, adalimumab, golimumab, and certolizumab, have
been licensed for clinical use in patients with RA [5,6],
approximately 40% of RA patients that have accepted those
anti-TNFa antibodies are non-responders. Importantly, inactiva-
tion of TNFa interferes with innate immune defense and
predisposes a risk of pathogenic infection. Moreover, joint repair
and erosion healing are rare despite effective therapies with TNFa
inhibitors [7,8]. Until now, therapeutic regimens sensitive,
effective and suitable for non-responders are unavailable because
no etiological initiators leading to RA have been validated. Given
these facts that TNFa is produced upon exposure to bacterial
components such as lipopolysaccharide (LPS) and other endotox-
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anti-microbial responses, and TNFa inhibitory biologic agents
render users at a raised risk of serious infection [9–11], it is
conceivable that TNFa blockers or antagonists should ameliorate
RA by abolishing infection-evoked TNFa, and also logically
reasonable that the onset of RA is likely attributed, in part, to
microbial pathogens.
Microorganisms have been implicated as the cause of many
rheumatic diseases, but there is no evidence supporting that
infectious agents are directly involved [12]. Most recently, a
surprising finding has emerged that the commensal Gram-positive
segmented filamentous bacteria (SFB) drives an autoimmune
disease in K/BxN mice with disease being abrogated under germ-
free conditions and restored after colonization with SFB [13]. To
this finding, a commentary annotation has been given that gut
microbiota-induced overproduction of interleukins (IL-1, IL-6, IL-
17, IL-22, and IL-23) may spill into systemic circulation and
promote autoimmune attacks at distant sites, such as joints [14].
Therefore, gut infection-activated interleukines are directly linked
to autoimmune-related articular lesions. We argue that, however,
interleukines are unlikely relevant to synovial hyperplasia seen in
RA, implying that alternative inducer(s) may exist to accelerate
tumor-like proliferation in the synovium.
A central role of nitric oxide (NO) in the pathogenesis of RA has
been previously suggested and currently pinpointed, but the
revealed mechanism is only restricted in NO-mediated immune
dysfunction [15,16]. From clinical data, we know that the inflamed
synovium is a predominant source of NO in patients with RA, and
T cells from RA patients produce 2.5 times more NO than the
healthy donor T cells [17,18]. Experimentally, blockade of TNFa
downregulates NO synthase (NOS) in human peripheral blood
mononuclear cells [19]. An engineered peptide of the growth factor
progranulin (PGRN), Atsttrin, is therapeutic against inflammatory
arthritisinmicethroughbindingtoTNFreceptorsto inhibit TNFa-
dependent NO production from macrophages [20]. Triptolide
extracted from Tripterygium wilfordii Hook F is effective for treatment
of experimental arthritis, probably due to inhibition of NOS by this
compound [21]. From all above results and other references
regarding bacterial infection-induced NOS in human neutrophils
[22] and NO-driven angiogenesis and carcinogenesis [23,24], we
assume that NO may be a candidate mediator initiating synovial
hyperplasia. Until recently, however, cumulative evendence
concerning NO-induced tumor-like synovial hyperplasia is trivial,
and the bona fide mechanism behind how NO drives synovial
hyperplasia also remains completely undefined.
To figure out a possible association of gastrointestinal bacterial
infection with inflammatory arthritis, we established a mouse
model of bacteria-induced arthritis (BIA) that simulates collagen II
(CII)-complete Freund’s adjuvant (CFA)-induced arthritis (CIA) by
daily live bacterial feeding. Dynamic changes of the serum level of
NO, along with the blood saturation percentage of oxygen (SpO2)
and the serum level of lactic acid (LA) were compared among
modeling mice. Furthermore, quantitative profiling of 40 kinds of
pro-inflammatory cytokines and immunoquantification of angio-
genesis-relevant hypoxia inducible factor 1 alpha (HIF-1a) and
vascular endothelial growth factor (VEGF) were performed during
modeling. Importantly, a conclusion indicating the potential
implication of NO in articular inflammation had been drawn
based on the result of an acute synovitis induced by the NO donor
compound sodium nitroprusside (SNP). Finally, we investigated
whether synovial inflammation could be compromised when
infection- or immunization-triggered NO was abolished by
administration of the antibiotic cefotaxime and/or the immuno-
suppressant rapamycin or artesunate. The present study pays
attention to elucidate whether sustained gastrointestinal bacterial
infection would represent one of the pathogenic initiators towards
RA, and to answer how NO could serve as a pivotal signal convey
bacterial infection to articular inflammation.
Results
Inflammatory articular lesions were correlated with
synovial hyperplasia and lymphocytic infiltration
The early-phase inflammatory articular lesions, mainly paws
becoming red and swollen, emerged after four-week daily feeding
of mice with live bacteria (about 10
8) derived from overnight
cultures of the non-pathogenic E. coli strain DH5a. In similar,
intra-dermal injection of mice with CII-CFA by primary
challenging on the 1st d and boosting on the 21st d also led to
redness and swelling of paws within four weeks (Figure 1A, B, and
C). CIA mice seemed to have developed more significant
inflammatory arthritis than BIA mice, suggesting that CII-CFA
was more effective than bacteria for modeling of experimental
arthritis in mice. While the severity was scored as eight in total or
two for each in CIA mice, only half of severity scores, i.e., four in
total or one for each, could be recorded for BIA mice.
Nevertheless, this result indicated that prolonged live bacterial
feeding could mimick CII-CFA immunization to cause a typical,
albeit mild, arthritic phenotype in mice.
To further identify the pathological alterations occurring in the
articulate of modeling mice, we conducted histopathological
analysis of the synovial tissue of BIA and CIA mice. In
histochemical sections of the inflamed synovium, no articular
damage and subintimal fibrosis were found, but multi-layer intimal
hyperplasia and mild synovial infiltration were observed
(Figure 1D, E, and F). Although the inflammatory extent in terms
of lymphocytic infiltration was nearly identical in both BIA and
CIA mice, a higher degree of intimal hyperplasia was exhibited by
CIA mice than BIA mice (Table 1). The histological alteration of
synovial hyperplasia was, therefore, mirrored in the phenotypical
manifestation of inflammatory events. This result revealed again
that persistent gut infection, even by non-pathogenic bacteria, also
provoked the onset of synovitis in susceptible mice.
Surprisingly, BIA-CIA mice established by live bacterial feeding
and synchronous intra-dermal CII-CFA injection was eventually
developed into synovitis after four weeks, but with only mild
morphological lesions and less histological damage (Figure 2A and
B). While CIA mice showed more severe lymphocytic infiltration,
BIA-CIA mice exibited only mild lymphocytic infiltration.
Additionally, co-treatment of mice by intra-articular CII-CFA
injection with live bacterial feeding also led to alleviated articular
inflammation and histological alterations within 3 d (Figure 2C
and D). These results implied that bacteria might exert an
immunosuppressive effect on CII-CFA-elicited immune activation
in BIA-CIA mice.
Cytokine antibody profiling validated global
upregulation of pro-inflammatory cytokines upon
infection or immunization
To follow up the immunological profile during the pathogenesis
of arthritis, we conducted antibody chip analysis on as many as 40
kinds of common cytokines, chemokines and receptors in BIA,
CIA and BIA-CIA mice (Figure 3A, B, and C). As results, all tested
pro-inflammatory cytokines were almost upregulated with some
downregulated in BIA and CIA mice, in which the most important
pro-inflammatory cytokines including interferon c (IFNc), inter-
leukins (IL), and colony-stimulating factors (CSF) were upregu-
lated. However, BIA-CIA mice showed an overall downregulation
Nitric Oxide as an Arthritis Initiator
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and IL-10 (Table 2). These results revealed a direct association of
pro-inflammatory cytokines with inflammatory arthritis.
TNFa represents a critical pro-inflammatory cytokine, but it
was not simultaneously upregulated in both BIA and CIA mice. As
seen from Table 2, TNFa was upregulated for 2.96 folds in BIA
mice, but downregulated to 60% in CIA mice. It was suggested
that the downregulation of TNFa in CIA mice might be resulted
from the decay of immune responses to earlier immunization
because several days had passed from CII-CFA injection to
cytokine profiling. On the other hand, TNFa receptors, sTNF RI
and sTNF RII, were upregulated in both BIA and CIA mice,
seeming to imply that TNF-TNFR signaling was actually
enhanced. In similar, sTNF RI and sTNF RII were among
upregulated cytokine receptors in BIA-CIA mice even though
most others were downregulated.
Potent NO burst occurred during development towards
arthritis and NO was reversely correlated with SpO2
To monitor the dynamic change of NO production during live
bacterial feeding and/or CII-CFA immunization, we determined
the serum NO level, in a time-course manner, in modeling mice.
Live bacterial feeding allowed the gradual elevation and
subsequent maintenance of a steady-state NO level, whereas
CII-CFA immunization led to the formation of double high NO
peaks, occurring immediately after the primary challenging on the
1st d and boosting on the 21st d. Interestingly, BIA-CIA mice
exhibited a similar pattern of peaked NO release with CIA mice
although their NO levels were relatively lower than CIA mice
(Figure 4A). Albeit in a distinct fashion and at a different extent, it
was common that potent NO burst had been triggered among all
modeling mice. As seen from the figure, much more NO was
detected in CIA mice (40 mM) than in BIA-CIA mice (25 mM) or
in BIA mice (20 mM) as compared in their highest levels. These
results clarified that CII (alloantigen) and live bacteria or dead
bacteria in CFA (xenoantigen) could stimulate an inducible release
of NO, thereby exerting a pathogenic effect.
To confirm the assumption of NO burst leading to hypoxia, we
monitored the fluctuation of SpO2 around the hind paws of
modeling mice. A dramatic decrease of SpO2 was determined
within erythematous and edematous paws of CIA mice. In
contrast, only a slight decrease of SpO2 was measured in BIA-CIA
and BIA mice (Figure 4B). Interestingly, lower SpO2 was
correlated with higher NO and vice versa in those arthritic mice.
For instance, 7 mM NO versus 80% SpO2 in control mice and
17 mM NO versus 50% SpO2 in CIA mice were detected,
respectively. A similar relationship between NO and SpO2 also
existed in mice with live bacterial feeding for 28 d, in which
control mice had a lower NO level (7.14 mM) and a higher SpO2
value (83.5%), whereas mice had a higher NO level (11.03 mM)
and a lower SpO2 value (69.5%).
Infection or immunization led to NO-correlated elevation
of LA and upregulation of HIF-1a and VEGF
To find out more direct evidence of NO-driven hypoxia, we
detected the serum levels of NO and LA, an end glycolytic
product, in BIA and CIA mice. A tight correlation of inducible
NO with increased LA was observed in mice with daily bacterial
feeding for 28 d or after 2 d of intra-articular CFA injection
Table 1. Semi-quantitative evaluation of histological damage
by a modified non-parametric scoring system in BIA and CIA
mice.
Intimal
hyperplasia
Subintimal
fibrosis
Lymphocytic
infiltration
Articular
damage
Control 0 0 0 0
BIA +++ 0 +++ 0
CIA ++++ 0 +++ 0
Note: The histological damage was scored after 28 d for articular sections of
modeling mice, in which BIA was induced by daily bacterial feeding; and CIA
was developed by twice immunizations (primary challenge and boosting).
doi:10.1371/journal.pone.0034494.t001
Figure 1. Morphological inflammation of erythematous and edematous paws and histochemical lesions of synovial hyperplasia
and inflammatory infiltration in BIA and CIA mice. A and D. Control; B and E. BIA mice; C and F. CIA mice. HE staining of sections and
microscopic analysis were carried out by sampling hind paws of mice after modeling for 28 d. The histochemical photographs were amplified for 100
folds.
doi:10.1371/journal.pone.0034494.g001
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anaerobic degradation of carbohydrates must be enhanced
following NO-driven hypoxia because it had eventually led to
LA accumulation in blood.
Furthermore, we also investigated the overexpression profiles of
angiogenesis-responsible genes in CIA mice. Consequently, both
HIF-1a and VEGF were upregulated in CIA mice after intra-
articular CFA injection (Figure 5C and D). Interestingly,
immunohistochemical staining of articular sections was dependent
on the amount of NO because subcutaneous injection of mice with
sodium nitroprusside (SNP), an exogenous NO donor compound,
enabled stronger staining for HIF-1a and VEGF in the hypoderm.
The positive signals from HIF-1a and VEGF were remarkably
enhanced in the hypoderm injected with 20 mg of SNP, up to
seven folds and four folds, respectively (Table 3).
From above results, it was clearly informed that either
endogenous NO provoked by immune activation or exogenous
NO supplied by SNP injection could equally induce articular
angiogenesis via driving synovial hypoxia that was characterized
by lower SpO2 values and higher LA levels in blood.
Administration of SNP mimicked inflammatory arthritis
seen in BIA or CIA mice
To address the implication of NO as an initiating factor of
inflammatory arthritis, we simply administered mice with SNP by
intra-articular injection. Fascinatingly, a single injection with SNP
could give rise to a distinguishable manifestation of edema on the
injected paw after only 1 d, legitimating a causitive effector leading
to inflammatory articular lesions (Figure 6A and B). As
expectation, similar inflammatory arthritis was observed in mice
injected with different amounts of CII-CFA (Figure 6C and D).
However, co-injection of mice with SNP and CII-CFA had
induced more severe arthritis (Figure 6E and F). These results
straightly demonstrated that exogenous NO could effectively serve
as an inducer of synovitis, and such a procedure of SNP-induced
acute arthritis might represent a novel and rapid approach for
modeling of RA-like arthritis in mice.
From measurement of the critical hypoxia parameter SpO2, it
was noticed that very low values of SpO2 (55–57%) were induced
in mice after injection with SNP regardless treatment with or
without CII-CFA. At the same time, different amounts of CII-
CFA could result in moderately lower values of SpO2 (62–66%),
which were lower than control mice (82%) but higher than SNP-
injected mice (Table 4). We were also aware from the table that
Figure 2. Morphological inflammation of erythematous and edematous paws and histochemical lesions of synovial hyperplasia
and inflammatory infiltration in BIA-CIA mice. A and B. BIA-CIA mice (intra-dermal CII-CFA injection); C and D. BIA-CIA mice (intra-articular CII-
CFA injection). HE staining of sections and microscopic analysis were carried out by sampling hind paws of mice after modeling of BIA-CIA mice (intra-
dermal CII-CFA injection) for 28 d and after modeling of BIA-CIA mice (intra-articular CII-CFA injection) for 3 d, respectively. The histochemical
photographs were amplified for 100 folds.
doi:10.1371/journal.pone.0034494.g002
Figure 3. Antibody chip profiling of pro-inflammatory cyto-
kines in blood of BIA, CIA and BIA-CIA mice. A. BIA mice; B. CIA
mice; C. BIA-CIA mice. For protein extraction and antibody hybridiza-
tion, whole blood was collected from mice after modeling for 28 d, and
40 kinds of cytokines, chemokines and receptors were quantitatively
analyzed.
doi:10.1371/journal.pone.0034494.g003
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severity of articular inflammation. For example, a higher SpO2
value (62%) rendered more significant edema on the paw injected
with CII-CFA. This result might imply that CII-CFA-triggered
immune activation must be implicated for the progression of
articular inflammation.
Anti-bacteria and NOS inhibition abrogated infection- or
immunization- triggered NO production and mitigated
hypoxic consequences
To validate bacterial infection is an inducer of NO generation,
we determined the serum level of NO in mice after live bacterial
Table 2. Global modulation of inflammation-related cytokines in blood of BIA, CIA and BIA-CIA mice.
Name of cytokines
Folds of BIA to
Control
Up-/down-
regulation
Folds of CIA to
Control
Up-/down-
regulation
Folds of BIA-CIA to
Control
Up-/down-
regulation
BLC 1.86 q 1.52 q 1.28 q
CD30 L 1.88 q 1.63 q 0.90 Q
Eotaxin 2.11 q 1.97 q 0.85 Q
Eotaxin-2 1.51 q 1.56 q 1.02 q
Fas Ligand 1.69 q 1.53 q 0.58 Q
Fractalkine 1.85 q 1.69 q 0.98 Q
G-CSF 1.66 q 1.46 q 1.21 q
GM-CSF 1.54 q 1.43 q 1.22 q
IFNc 1.12 q 1.27 q 0.93 Q
IL-1a 1.00 Q 0.95 Q 0.75 Q
IL-1 b 0.71 Q 1.14 q 0.47 Q
IL-2 1.05 q 1.08 q 0.55 Q
IL-3 0.80 Q 0.95 Q 0.49 Q
IL-4 1.62 q 1.31 q 0.98 Q
IL-6 1.58 q 1.22 q 0.08 Q
IL-9 1.73 q 1.60 q 0.68 Q
IL-10 1.88 q 1.20 q 0.36 Q
IL-12p40p70 2.05 q 1.89 q 0.87 Q
IL-12p70 1.23 q 1.06 q 0.90 Q
IL-13 1.49 q 0.94 Q 1.39 q
IL-17 1.07 q 1.67 q 0.23 Q
I-TAC 2.02 q 2.22 q 1.27 q
KC 1.86 q 1.75 q 0.74 Q
Leptin 1.73 q 1.35 q 1.01 q
LIX 1.19 q 1.27 q 1.22 q
Lymphotactin 1.93 q 1.38 q 0.98 Q
MCP-1 1.75 q 1.53 q 0.95 Q
M-CSF 1.41 q 1.23 q 0.88 Q
MIG 2.04 q 1.37 q 0.81 Q
MIP-1a 1.64 q 1.31 q 0.98 Q
MIP-1c 0.99 Q 0.96 Q 1.04 q
RANTES 2.03 q 1.40 q 1.88 q
SDF-1 1.44 q 1.29 q 0.91 Q
TCA-3 1.50 q 1.18 q 0.88 Q
TECK 2.60 q 1.53 q 0.55 Q
TIMP-1 2.40 q 1.42 q 0.79 Q
TIMP-2 1.66 q 0.89 Q 0.66 Q
TNFa 2.96 q 0.59 Q 0.25 Q
sTNF RI 1.88 q 1.42 q 1.27 q
sTNF RII 1.87 q 1.53 q 2.23 q
Note: The antibody-based microarry analysis of cytokines, chemokines, and receptors was conducted after 28 d for blood of modeling mice, in which BIA was induced
by daily bacterial feeding; CIA was developed by twice immunizations (primary challenge and boosting); and BIA-CIA was established by daily bacterial feeding and
twice immunizations (primary challenge and boosting).
doi:10.1371/journal.pone.0034494.t002
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inhibitor artesunate, the antibiotic cefotaxime, or the combination
of artesunate with cefotaxime for 3 d (twice a day). As illustrated in
Figure 7A, artesunate, cefotaxime, or artesunate+cefotaxime
considerably decreased NO production, and the serum level of
NO in the combined treatment group was even lower than the
control. Conceivably, artesunate decreased the serum NO levels
due to the inhibition of NOS activity even though infection still
existed. Cefotaxime allowed a serum level of NO equal to the
control because of infection blocking. The combined treatment of
bacteria-fed mice by artesunate with cefotaxime lowered the
serum NO level below that seen in the control owing to dual
effects of infection suppression and NOS inhibition. These results
verified that persistent gastrointestinal infection did trigger potent
NO burst in mice, but this outcome could be mitigated or
abrogated by anti-bacteria and/or NOS inhibition.
Because no significant inflammatory symptoms occurred after a
short period (7 d) of bacterial feeding in mice, the severity of
bacteria-induced synovitis could not be scored and a potential
anti-arthritic effect of artesunate and/or cefotaxime was also
difficult to be evaluated. However, therapeutic efficacy of
cefotaxime, phytol, alcohol, or a combination on BIA could be
reflected from either the amelioration of morphological alterations
in mice with live bacterial feeding for more than one month or the
normalization of hypoxic parameters including NO, LA and SpO2
in mice at any time points during live bacterial feeding. Table 5
listed those data of hypoxic parameters determined before and
after anti-bacterial or other treatments in BIA mice. Interestingly,
anti-bacterial treatment by cefotaxime injection or diluted alcohol
drinking demonstrated an eradication of hypoxic consequences,
whereas the oxidative burst inducer phytol showed only a partial
normalization of hypoxic parameters.
In CIA mice established by intra-dermal or intra-articular CII-
CFA immunization, NO was dramatically decreased to a level
lower than the control after artesunate or rapamycin administra-
tion. Combined application of artesunate with rapamycin, or
rapamycin with alcohol in BIA-CIA mice led to considerably
repressed NO production. In particular, an extremely lower NO
level (0.448 mM) was detected in one artesunate-administered CIA
mouse. In contrast, untreated BIA-CIA and CIA mice exhibited
much higher NO levels, up to 10 mM in the maximum (Figure 7B).
Intriguely, untreated CIA mice even gave rise to a low NO level
almost equal to that of the control, which might be attributed to a
decay effect of CII-CFA-triggered NO production after longer
duration of post-immunization. Actually, three weeks had passed
from CII-CFA boosting to NO detection.
NO scavenging also mitigated articular inflammation
albeit to a different extent
According to morphological and histochemical identifications of
the inflamed synovium, amelioration of articular synovitis could be
practically confirmed in anti-arthritic drug-treated mice although
their merits were not on average levels. In mice with intra-articular
CII-CFA injection, synchronous administration of artesunate or
rapamycin had kept the synovium intact from intimal hyperplasia
and subintimal fibrosis. However, dispersed synovial infiltration by
inflammatory lymphocytes was still observed in the artesunate-
treated group, but not in the rapamycin-treated group (Figure 8A
and B). These results indicated that artesunate as an inhibitor of
NOS only suppressed hyperplasia, while rapamycin as an
immunosuppressant that can block immune activation-dependent
NO production could attenuate both hyperplasia and infiltration.
Among CIA mice, post-treatment by artesunate and rapamycin
aborted both intimal hyperplasia and subintimal fibrosis, but failed
to recover the synovium from mild and dispersed inflammatory
infiltration by mononucleates. On the other hand, co-administra-
tion of CIA mice with rapamycin and alcohol did not hamper the
progression to local synovial hyperplasia and mild lymphocytic
infiltration (Figure 8C and D). Post-injection of BIA-CIA mice
with artesunate and rapamycin abolished subintimal fibrosis and
inflammatory infiltration, but intimal hyperplasia could not be
prohibited completely. In contrast, rapamycin and alcohol
treatment could remit the hyperplasic synovium, but did not
inhibit progression to mild and dispersed inflammatory infiltration
(Figure 8E and F).
Above outcomes of therapeutic regimens demonstrated, there-
fore, that pre-treatment prior to NO generation was more effective
than post-treatment after NO generation. In other words, synovial
damage made prior to drug administration failed to be
ameliorated by any regimen of above post-treatments. These
Figure 4. Dynamic monitoring of NO production and comparative analysis of relationship between NO and SpO2 in BIA, CIA and
BIA-CIA mice. A. Time-course detection of serum NO levels in BIA, CIA and BIA-CIA mice (n=3). Sampling and detection were conducted every 5 d
and until 25 d during modeling; B. Measurement of SpO2 and NO in BIA, CIA and BIA-CIA mice (n=4). Sampling and detection were conducted after
modeling for 3 d in CIA and BIA-CIA mice or after modeling for 28 d in BIA mice. The singular asterisk (*) represents statistically significant difference
from the control (P,0.05); and double asterisks (**) indicate statistically very significant difference from the control (P,0.01).
doi:10.1371/journal.pone.0034494.g004
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of RA-like arthritis, mainly responsible for synovial hyperplasia, so
NO-initiated synovial lesions might not be reversible by any NOS
inhibitors.
Discussion
As a gaseous free radical with pleiotropic functions in biological
systems, NO is produced from the oxidation of L-arginine to L-
citrulline by the catalysis of either isoform of three types of NOS:
inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal
NOS (nNOS) [25]. Through generating the inducible NO during
pathogenic infection, iNOS is involved in immune attack against
active invaders. For instance, bacterial infection of human colon
epithelial cells rapidly upregulates iNOS expression and enhances
NO production [26]. Apart from gastrointestinal infection
following live bacterial feeding, however, we found that immuni-
zation of mice with CII-CFA could also provoke potent NO burst,
hence suggesting that NO production was dependent on immune
activation regardless of pathogenic infection.
Arthritis modeling in mice has been generally considered to
require heat-killed Mycobacterium tuberculosis-containing CFA in
addition to CII, strongly implying that anti-CII responses are
insufficient to induce arthritis in mice. Some authors thought that
anti-CII reactivity might be a consequence of inflammation rather
than the cause [27]. This is why so many kinds of autoantibodies
were formed in RA patients or experimental arthritic rodents, such
as those against citrullinated proteins, glucose-6-phosphate
isomerase, integrin, and fibrin, etc. [28–31]. So we assume that
CII is probably indispensable for modeling RA, at least inducing
synovitis, in mice. Indeed, we have successfully induced acute
arthritis in mice by intra-articular injection with CFA alone
instead of CII-CFA (unpublished results). Therefore, we draw a
conclusion here that any immune activators including autoanti-
Figure 5. NO-driven hypoxia and angiogenesis in BIA and CIA mice. A. Serum NO and LA levels in BIA mice (n=3); B. Serum NO and LA levels
in CIA mice (n=3); C. Immunohistochemical staining against HIF-1a in the articular synovium of CIA mice (6200); D. Immunohistochemical staining
against VEGF in the articular synovium of CIA mice (6200). Sampling and detection were conducted after modeling for 3 d in CIA mice. The singular
asterisk (*) represents statistically significant difference from the control (P,0.05); and double asterisks (**) indicate statistically very significant
difference from the control (P,0.01).
doi:10.1371/journal.pone.0034494.g005
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corresponding immune responses and confer inflammatory lesions
by triggering NO generation and driving hypoxic consequences.
The mucosal response to enteric infection includes the
production of chemoattractant cytokines (chemokines), anti-
inflammatory cytokines, and pro-inflammatory cytokines, in which
TNFa is the most important pro-inflammatory cytokine that can
amplify the epithelial immune response to bacterial infection [32].
TNFa, IL-1b and other pro-inflammatory cytokines can upregu-
late NOS in chondrocytes and synovial cells of osteoarthritis [33].
We have also observed the global activation of more than 30
kinds of chemokines, cytokines and receptors in BIA and CIA
mice, including TNFa, IL-1b, IL-6, M-CSF, and MCP-1, which
were capable of driving a complex and chronic inflammatory
process [34]. In the present study, an experimental outcome that
TNFa was downregulated in CIA mice was puzzling, but it was
most likely attributed to the attenuation of immune responses to
CII-CFA after experenced for several weeks of immunization. As
noticed, NO levels were declined twice (15
th d and 25
th d) in CIA
mice to levels approaching to those seen in the control during
modeling. In fact, sampling for cytokine chip profiling was carried
out after modeling for 30 d. Indeed, a higher serum level of TNFa,
as two folds as the control, was measured in mice after 3 d of intra-
articular injection with CII-CFA (unpublished results).
Although the implication of NO in the pathogenesis of
experimental arthritis is poorly understood, CII-CFA-triggered
NO burst had been noticed in CIA mice [35]. We also observed
that two NO peaks were formed immediately after primary
challenging and boosting with CII-CFA, whereas a stable level of
NO higher than the control maintained in the course of daily live
bacterial feeding. Albeit in a distinct manner, either CII-CFA or
bacteria did provoke NO production, permanently or transiently,
in BIA and CIA mice. Nevertheless, whether an extraordinarily
higher level of NO only initiating or even controlling the
Table 3. SNP-induced overexpression of HIF-1a and VEGF in the SNP-injected hypoderm of mice (n=3).
Treatment
Surface density
(mm) Positive unit (PU)
Immunohistochemical staining
strength
HIF-1a
Control 0.06360.05 33.59066.85 2.02561.33
2 mg SNP (10 mg/ml) 0.35860.06 18.66063.60 6.69461.82*
10 mg SNP (50 mg/ml) 0.24260.06 31.00363.69 7.49362.16*
20 mg SNP (100 mg/ml) 0.41060.04 34.41062.94 14.06761.23**
VEGF
Control 0.08760.01 24.86761.66 2.16960.39
2 mg SNP (10 mg/ml) 0.22960.04 19.20767.60 4.21961.27*
10 mg SNP (50 mg/ml) 0.22260.08 22.07766.87 4.64660.88*
20 mg SNP (100 mg/ml) 0.31060.08 26.09060.87 8.10562.05**
Note: The immunohistochemical analysis was performed after 12 d for hypodermal sections of mice with daily injection of SNP (once a day), and the injected valume of
SNP was 200 ml in all groups of treatments. The immunohistochemical staining strength was calculated from the formula of the surface density6the positive unit (PU),
where the surface density represents the total area of positive loci/the total area for calculation. The singular asterisk (*) represents statistically significant difference
from the control (P,0.05); and double asterisks (**) indicate statistically very significant difference from the control (P,0.01).
doi:10.1371/journal.pone.0034494.t003
Figure 6. Articular inflammatory manifestations in mice after intra-articular injection with SNP, CII-CFA, or combined SNP and CII-
CFA. A. Control; B. 20m g SNP-injected mice; C. 40 mg CII-CFA-injected mice; D. 20 mg SNP+40 mg CII-CFA-injected mice; E. 4 mg CII-CFA-injected mice;
F. 20 mg SNP+4 mg CII-CFA-injected mice. All photographes were taken after injection with SNP, CII-CFA, or combined SNP and CII-CFA for 1 d.
doi:10.1371/journal.pone.0034494.g006
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other hand, we also found that co-treatment by CII-CFA
immunization with live bacterial feeding could allow the global
downregulation of pro-inflammatory cytokines including TNFa,
IL-1b and IL-6, hence suggesting an immunosuppressive role of
bacteria upon CII-CFA-activated immune responses. In consis-
tence with our findings, Schistosoma japonicum infection has been
reported to significantly attenuate the clinical signs, to reduce the
histological damage, to alter the humoral immune responses, and
to inhibit the splenocyte proliferation in CIA mice [36].
Additionally, immunosuppression by bacteria has been addressed
in a recently published review [37]. Therefore, it is believed that
arthritic development might be mostly dependent on systemic
immune activation, and immunosuppression can, of couse,
alleviate inflammatory arthritis.
Rapamycin is a well-known immunosuppressant that reduces
pannus formation, cartilage erosion and joint damage in rats with
adjuvant-induced arthritis [38]. Artesunate also plays an anti-
arthritic role in CIA mice [39]. Even though the pharmacological
mechanisms of rapamycin and artesunate as therapeutic agents of
arthritis are thought to be multifaceted, no experimental records
have been documented regarding their suppression on NO
production and potential preventive effects on arthritis. In the
present study, we have linked, for the first time, the abrogation of
inflammatory arthritis with the repression of NO generation in
mice that had accepted rapamycin and/or artesunate prior to
modeling. Synchronous administration of such anti-arthritic drugs
to CII-CFA immunized mice could effectively block the onset of
synovitis or hamper its aggravation towards arthritis. However,
drug combinations for post-treatment in the present regimen never
completely repaired the damaged synovium of modeling mice.
Nevertheless, anti-bacterial and/or pro-apoptotic treatments by
cefotaxime, alcohol, phytol or a combination of multi-drugs in live
bacterial feeding mice seemed to improve the inflamed synovium
at a certain extent, being reflected from the normalization of
hypoxic parameters, NO, LA, and SpO2. Cefotaxime could
dramatically decrease the level of NO, LA, and SpO2 to control
levels. Phytol, alcohol, or their combination could more or less
normalize those hypoxic parameters. Support evidence to a
conclusion of diluted alcohol being beneficial to RA patients has
been reported in a clinical cohort that alcohol consumption is
inversely associated with risk and severity of RA [40]. On the other
hand, phytol as an oxidative burst inducer has been used for
treatment of experimental arthritis, from which decreased
autoimmune responses and amelioration of both the acute and
chronic phases of arthritis have been reported in rats [41].
From the histochemical analysis of articular sections prepared
from the synovial and articular tissue of BIA and CIA mice, we
observed remarkable synovial hyperplasia, an indicative hint of
angiogenesis and tumorigenesis. It has been previously filed that
angiogenesis is an early event in the inflammatory joint that is
important in enabling activated monocytes to enter the synovium
Table 4. Comparison of SpO2 in articulates of mice after intra-
articular injections by SNP, CII-CFA, or SNP+CII-CFA (n=3).
Treatment SpO2 (%)
Control 81.6761.15
20 mg SNP (100 mg/ml) 56.6762.08**
40 mg CII-CFA (200 mg/ml) 61.6763.79*
40 mg CII-CFA+20 mg SNP (200 mg/ml
CII-CFA+100 mg/ml SNP)
54.6762.89**
4 mg CII-CFA (20 mg/ml) 64.3362.52*
4 mg CII-CFA+20 mg SNP (20 mg/ml
CII-CFA+100 mg/ml SNP)
54.6760.58**
Note: SpO2 was measured after 3 d for articulates of mice with intra-articular
SNP, CII-CFA, or SNP+CII-CFA. The injected valume of each drug or a drug
combination was 200 ml in all groups of treatments. The singular asterisk (*)
represents statistically significant difference from the control (P,0.05); and
double asterisks (**) indicate statistically very significant difference from the
control (P,0.01).
doi:10.1371/journal.pone.0034494.t004
Figure 7. Abrogation of NO production after anti-bacteria and/or NOS inhibition in BIA, CIA and BIA-CIA mice. A. Serum NO levels in
drug-administered BIA, CIA and BIA-CIA mice (n=3). The serum NO level was determined after anti-bacteria and/or NOS inhibition of modeling mice
by 60 mg/ml artesunate, 50 mg/ml rapamycin, 15% alcohol or a combination of drugs; B. Serum NO levels in bacteria-fed or antibiotic-administered
mice (n=10). The serum NO level was determined after live bacterial feeding for 7 d and injecting artesunate, cefotaxime, or the combination of
artesunate with cefotaxime for 3 d (twice a day). ART: artesunate; CEF: cefotaxime; RAP: rapamycin; ALC: alcohol. The singular asterisk (*) represents
statistically significant difference from the control (P,0.05); and double asterisks (**) indicate statistically very significant difference from the control
(P,0.01).
doi:10.1371/journal.pone.0034494.g007
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recruitment, resulting in cartilage degradation and bone destruc-
tion [42]. Hypoxia is capable of inducing the expression of
angiogenesis-related genes including hypoxia inducible factor 1
alpha (HIF-1a) and vascular endothelial growth factor (VEGF)
[43]. Alternatively, NO can also activate HIF-1a under normoxic
conditions [44], hence implying NO as a hypoxic inducer. We
found that supplementation with exogenous NO through SNP
injection could effectively induce synovitis, and also cause
hypodermal neoplasia in mice (unpublished results), thereby
suggesting that NO-driven angiogenesis is a setpoint towards
hyperplasia.
The synovium itself covering the articular organ is a relatively
hypoxic tissue, in which oxygen tension in cartilage ranges from
7% (53 mm Hg) in the superficial layer to less than 1%
(7.6 mm Hg) in the deep zone [45]. As a result, hemoglobin
carrying with NO can not supply sufficient O2 to the synovium
under hypoxic conditions, and NO can also accelerate its own
consumption by increasing its entry into red blood cells [46]. NO
inhibits the mitochondrial enzyme cytochrome c oxidase (complex
IV) in competition with O2, leading to so-called ‘‘metabolic
hypoxia’’ – a situation in which, although oxygen is available, the
cell is unable to utilize it [47]. High levels of NO inhibit cell
respiration by binding to cytochrome c oxidase, whereas slow
and small-scaled NO release can stimulate mitochondrial
biogenesis in diverse cell types [48]. Our results indicated that
enhanced NO production was correlated with lower SpO2
values, seeming to reveal a direct consequence of NO leading
to SpO2. It is most likely that NO drives hypoxia by competing
O2 that has been bound to the hemoglobin or preferen-
tially occupying the O2-binding site of the non-oxygenated
hemoglobin. Such knowledge should convince us that NO conveys
Table 5. Measurement of hypoxic parameters for evaluation of cefotaxime on bacteria fed mice (n=4).
Treatment NO (mM) LA (mM) SpO2 (%)
Control 7.1560.30 7.8860.13 83.0061.83
BIA (one-month live bacterial feeding) 9.8760.48* 12.5860.19** 70.5062.08*
BIA treated by 3 mg CEF (15 mg/ml) for 3 d 2.9760.13** 7.8360.07 80.5060.71
BIA treated by 3 mg CEF (15 mg/ml) for 5 d 3.1260.15** 7.9160.05 82.5060.71
BIA treated by 12 mg PTL (60 mg/ml) for 3 d 5.1460.13* 6.7960.05 69.5060.71*
BIA treated by 12 mg PTL (60 mg/ml) for 5 d 4.6260.15* 11.5060.05** 78.5060.71
BIA treated by 3 mg CEF (15 mg/ml)+12 mg PTL (60 mg/ml) for 3 d 7.5760.26 14.3660.05** 75.5060.71
BIA treated by 3 mg CEF (15 mg/ml)+12 mg PTL (60 mg/ml) for 5 d 4.8460.15* 13.5760.05** 80.5060.71
BIA treated by 15% ACL+12 mg PTL (60 mg/ml) for 3 d 7.3060.13 6.7960.05 76.5060.71
BIA treated by 15% ACL+12 mg PTL (60 mg/ml) for 5 d 5.9160.15* 8.3260.05 76.5060.71
Note: NO, LA, and SpO2 were measured in mice with live bacterial feeding or after drug administration for 3 d or 5 d. The injected valume of each drug or a drug
combination was 200 ml in all groups of treatments. The singular asterisk (*) represents statistically significant difference from the control (P,0.05); and double asterisks
(**) indicate statistically very significant difference from the control (P,0.01). CEF: cefotaxime for subcutaneous injection; PTL: phytol for intra-articular injection; ACL:
alcohol for drinking.
doi:10.1371/journal.pone.0034494.t005
Figure 8. Histological amelioration of synovitis by anti-arthritis therapies in CIA and BIA-CIA mice (HE staining,6200). A and B. Pre-
treatment of CIA (intra-articular CII-CFA injection) mice with 60 mg/ml artesunate or 50 mg/ml rapamycin; C and D. Post-treatment of CIA (intra-dermal
CII-CFA injection) mice with 60 mg/ml artesunate and 50 mg/ml rapamycin, or 50 mg/ml rapamycin and 15% alcohol; E and F. Post-treatment of BIA-
CIA (intra-dermal CII-CFA injection) mice with 60 mg/ml artesunate and 50 mg/ml rapamycin, or 50 mg/ml rapamycin and 15% alcohol. HE staining of
sections and microscopic analysis were carried out by sampling hind paws of mice after therapy completion.
doi:10.1371/journal.pone.0034494.g008
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ronment.
Due to NO-mediated hypoxic effects, blood carbohydrates were
anaerobically catabolized and glycolytic metabolites were neces-
sarily converted to LA, which would be accumulated in the
systemic blood stream unless oxygen supply was rehabilitated. In
the present investigation, we monitored the dynamic changes of
serum NO and LA levels synchronously, and found a proportional
fluctuation of NO with LA in arthritic modeling mice. The serum
level of LA is obviously a new reference parameter for quantifying
hypoxia in addition to SpO2, and LA can also indicate the
transversion from hypoxia to normoxia. Furthermore, it has been
known that hypoxia can activate the responded transcriptional
factor HIF-1a, which in turn binds to the promoter of VEGF gene
for starting transcription and translation [49]. We detected the
overexpression of HIF-1a and VEGF in the inflamed synovium of
acute CIA mice albeit only in a moderate degree. When
exogenous NO derived from SNP was supplemented into the
hypoderm of mice, much higher expression levels of HIF-1a and
VEGF than those seen in acute CIA mice were detected, thereby
suggesting a reliable relevance of NO-driven overexpression of
HIF-1a and VEGF with synovial as well as systemic angiogenesis
during tissue hyperplasic induction.
In view of different roles playing by NO and pro-inflammatory
cytokines, we believe that both of which are important in
determining the initiation and progression of inflammatory
arthritis in mice. It is possibly that NO is mainly responsible for
synovial hyperplasia, whereas pro-inflammatory cytokines are
relevant to inflammatory infiltration. NO may induce synovial
angiogenesis and hyperplasia by NO-mediated hypoxia, which can
subsequently guide pro-inflammatory cytokines penetrating deeply
into the synovium along with the newborn blood vessel [50]. Our
results in experimental arthritis in mice indicated that NO
promoted angiogenesis by activating HIF-1a and VEGF and in
turn mitigated glycolysis after enhanced angiogenesis. These
results would become a basis for treatment of arthritis by the
inhibition of NO-driven angiogenesis. Currently published data
have demonstrated that anti-VEGF treatment by bevacizumab
reduces blood supply, increases glycolytic metabolites, and
promotes tumor metastasis in glioblastoma [51], underlining that
no amelioration would be reached if inflammation-originated
hypoxia has not been alleviated or abrogated.
In conclusion, our present study have answered a long-term
unanswered question about the association of distal or systemic
infection with inflammatory arthritis: gastrointestinal infection can
serve as an etiological initiator of inflammatory arthritis by dually
upregulating pro-inflammatory cytokines to allow lymphocytic
infiltration and triggering NO to drive synovial hypoxia and
hyperplasia. These achievements should shed light on the
prophylactic and therapeutic interventions of RA and other
human autoimmune diseases in the future clinical trials.
Materials and Methods
Induction of experimental arthritis in mice
Male KM mice (7–8 weeks old, 20–22 g) were provided by The
Experimental Animal Center of Guangzhou University of Chinese
Medicine, China. All animal experiments in the present study
were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (NIH), USA. The protocol was
approved by the Animal Care Welfare Committee of Guangzhou
University of Chinese Medicine (Permit Number: SPF-2011007).
To perform gastrointestinal bacterial infection, an overnight
culture of the non-pathogenic E. coli strain DH5a in 10
8 cells
was mixed with food for daily feeding of mice. To conduct intra-
articular or intra-dermal CII-CFA immunization, CII (Sigma-
Aldrich, USA) was dissolved in 0.1 M acetic acid (2 mg/ml) and
emulsified with equal amounts of CFA (Sigma-Aldrich, USA) for
injection into the unilateral ankle articular cavity or at the tail
base, and primarily challenged mice were boosted with the same
CII-FCA mixture after three weeks [52]. The severity of
inflammatory arthritis was measured by scoring each limb from
0 to 4 grades and by summing up the clinical scores of four limbs:
0=normal; 1=erythema or edema of one or several digits;
2=erythema and moderate edema extending from the ankle to
the mid-foot (tarsals); 3=erythema and severe edema extending
from the ankle to the metatarsal joints; and 4=complete erythema
and edema encompassing the ankle, foot and digits, resulting in
deformity and/or ankylosis [53].
Determination of serum NO, LA and blood SpO2
NO and LA were determined using commercially available kits
(Nanjing Jiancheng, China) and according to the manufacturer’s
instruction. The serum level of NO was calculated from the
formula: NO (mM)=(OD550 test-OD550 blank/OD550 stan-
dard-OD550 blank)6C standard (20 mM)6dilution fold (1 fold).
The serum level of LA was calculated from the formula: LA
(mM)=(OD530 test-OD530 blank/OD530 standard-OD530
blank)6C standard (3 mM)6dilution fold (7 folds). Blood SpO2
was measured by inserting a hind paw or the injected paw into the
cavity of a blood SpO2 photometer MD300C (Beijing Chaosi
Electronics, China). The value showing on the LED screen is
SpO2 (%).
Protein extraction and cytokine antibody chip analysis
Protein extraction from blood cells by Cell & Tissue Protein
Extraction Reagent (KangChen KC-415) was conducted accord-
ing to the manufacturer’s instruction. Cytokine antibody array was
carried out by KangChen Bio-Tech, Shanghai, China using
RayBioH Mouse Cytokine Antibody Array and according to the
manufacturer’s manual as following steps: Blocking and incuba-
tion, detection, and result interpretation (http://www.kangchen.
com.cn/support/Supportmain.asp?ID=129).
Articular sampling and histochemical staining
Formalin-fixed and paraffin-embedded joint tissues (including
synovium and cartilage) were cut at a thickness of 5 mm. Sections
were deparaffinized by xylene, re-hydrated by gradient alcohol,
and washed in distilled water. After hematoxylin staining, washing
in running tap water, differentiation in 1% acid alcohol, washing
in running tap water, bluing in 1% ammonia, washing in running
tap water, and rinsing in 95% alcohol was performed. After eosin
counter staining, dehydration through gradient alcohol, clearance
in xylene, and mount with xylene-based mounting medium. Semi-
quantitative analysis of sections was carried out by light
microscopy equipped with a camera using a modified non-
parametric scoring system [54], in which 0, +, ++, +++,
and++++for each criteria of normal, intimal hyperplasia, subin-
timal fibrosis, lymphocytic infiltration, and articular damage were
evaluated, respectively.
Immunohistochemical quantification
Formalin-fixation, paraffin-embedment and deparaffinization
were the same as HE staining procedure described above. Sections
were incubated at room temperature with 3% H2O2 to block
endogenous peroxidases, and then repaired in boiling citric acid.
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blocked by 2% bovine serum albumin (BSA) and incubated with
1:100 diluted primary antibodies at 37uC for 1 h. After washing
with PBS, sections were incubated with biotinylated secondary
antibodies at 37uC for 20 min. After washing with PBS, sections
were incubated with diaminobenzidine (DAB) for 1–5 min. After
rinsing with tap water, sections were counter stained by
hematoxylin. After completion of dehydration, clearance and
mounting, pictures were taken under the microscope (OLYMU-
PUS BX-51) and immunoquantitatively analyzed by the MIAS
microimage analysis system (Beijing, China). The quantitative
result was calculated based on the formula: The immunohisto-
chemical staining strength=the surface density6the positive unit
(PU), where the surface density represents the total area of positive
loci/the total area for calculation.
Statistical analysis
The difference of value in each assessment was analyzed by
Student t test. A P value of less than 0.05 is statistically significant
(*), and a P value of less than 0.01 is statistically very significant
(**). All data were analyzed using SPSS version 10.0 for Windows.
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